# A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function

> **NCT03902002** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 48 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Omaveloxolone 50 mg capsules

## Key facts

- **NCT ID:** NCT03902002
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-19
- **Primary completion:** 2020-01-27
- **Final completion:** 2020-01-27
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03902002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03902002, "A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03902002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*